Witjes, J. Alfred and Babjuk, Marek and Bellmunt, Joaquim and Bruins, H. Maxim and De Reijke, Theo M. and De Santis, Maria and Gillessen, Silke and James, Nicholas and Maclennan, Steven and Palou, Juan and Powles, Tom and Ribal, Maria J. and Shariat, Shahrokh F. and Van der Kwast, Theo and Xylinas, Evanguelos and Agarwal, Neeraj and Arends, Tom and Bamias, Aristotle and Birtle, Alison and Black, Peter C. and Bochner, Bernard H. and Bolla, Michel and Boormans, Joost L. and Bossi, Alberto and Briganti, Alberto and Brummelhuis, Iris and Burger, Max and Castellano, Daniel and Cathomas, Richard and Chiti, Arturo and Choudhury, Ananya and Comperat, Eva and Crabb, Simon and Culine, Stephane and De Bari, Berardino and De Blok, Willem and De Visschere, Pieter J. L. and Decaestecker, Karel and Dimitropoulos, Konstantinos and Dominguez-Escrig, Jose L. and Fanti, Stefano and Fonteyne, Valerie and Frydenberg, Mark and Futterer, Jurgen J. and Gakis, Georgios and Geavlete, Bogdan and Gontero, Paolo and Grubmueller, Bernhard and Hafeez, Shaista and Hansel, Donna E. and Hartmann, Arndt and Hayne, Dickon and Henry, Ann M. and Hernandez, Virginia and Herr, Harry and Herrmann, Ken and Hoskin, Peter and Huguet, Jorge and Jereczek-Fossa, Barbara A. and Jones, Rob and Kamat, Ashish M. and Khoo, Vincent and Kiltie, Anne E. and Krege, Susanne and Ladoire, Sylvain and Lara, Pedro C. and Leliveld, Annemarie and Linares-Espinos, Estefania and Logager, Vibeke and Lorch, Anja and Loriot, Yohann and Meijer, Richard and Mir, M. Carmen and Moschini, Marco and Mostafid, Hugh and Mueller, Arndt-Christian and Mueller, Christoph R. and N'Dow, James and Necchi, Andrea and Neuzillet, Yann and Oddens, Jorg R. and Oldenburg, Jan and Osanto, Susanne and Oyen, Wim J. G. and Pacheco-Figueiredo, Luis and Pappot, Helle and Patel, Manish and Pieters, Bradley R. and Plass, Karin and Remzi, Mesut and Retz, Margitta and Richenberg, Jonathan and Rink, Michael and Roghmann, Florian and Rosenberg, Jonathan E. and Roupret, Morgan and Rouviere, Olivier and Salembier, Carl and Salminen, Antti and Sargos, Paul and Sengupta, Shomik and Sherif, Amir and Smeenk, Robert J. and Smits, Anita and Stenzl, Arnulf and Thalmann, George N. and Tombal, Bertrand and Turkbey, Baris and Lauridsen, Susanne Vahr and Valdagni, Riccardo and Van der Heijden, Antoine G. and Van Poppel, Hein and Vartolomei, Mihai D. and Veskimae, Erik and Vilaseca, Antoni and Rivera, Franklin A. Vives and Wiegel, Thomas and Wiklund, Peter and Williams, Andrew and Zigeuner, Richard and Horwich, Alan (2020) EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees. EUROPEAN UROLOGY, 77 (2). pp. 223-250. ISSN 0302-2838, 1873-7560
Full text not available from this repository. (Request a copy)Abstract
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and <= 15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder canceir management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistake-holder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available. (C) 2019 European Society of Medical Oncology and European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METASTATIC UROTHELIAL CARCINOMA; TRANSITIONAL-CELL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; LONG-TERM-SURVIVAL; RADICAL CYSTECTOMY; PROGNOSTIC-FACTORS; LYMPHOCYTE RATIO; TUMOR RESPONSE; SINGLE-ARM; FOLLOW-UP; Bladder cancer; Consensus; Delphi; Diagnosis; Treatment; Follow-up |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 Mar 2021 10:32 |
| Last Modified: | 31 Mar 2021 10:32 |
| URI: | https://pred.uni-regensburg.de/id/eprint/45289 |
Actions (login required)
 |
View Item |
